Li Tao of Bristol-Myers Squibb will preside over this afternoon symposium which presents experts from both academia and industry discussing recent advances and current practice in analytics for therapeutic proteins.
Li Tao of Bristol-Myers Squibb will preside over this afternoon symposium, in room 118A, which presents experts from both academia and industry discussing recent advances and current practice in analytics for therapeutic proteins.
The first presentation will be from Richard Rianto Rustandi of Merck & Company. “Applications of an Automated and Quantitative CE-based Size, Charge and Western Blot for Therapeutic Proteins and Vaccines Development” is the title of his talk, which presents two capillary electrophoresis-based methods that are now an industry standard and are an expectation of the regulatory agencies for biologics characterization.
Carlito Lebrilla of the University of California will follow with a talk titled “A Rapid Throughput Method for the Characterization of Glycosylation in Biologics Produced from Plants.” Lebrilla will discuss a method that is sensitive and fast and is used to monitor changes in glycosylation during production using different expression systems including animal cells and plants.
Next, Melissa Ly of Pfizer will present “Evaluating Glycation in Antibodies by Heighted Characterization with Mass Spectrometry.” Ly will demonstrate the use of a reduction step using sodium borohydride to stabilize glycation, followed by chymotrypsin proteolytic digestion conditions, improves LC–MS/MS analysis for site localization and relative quantitation of both minor and trace level glycation.
Following the recess, Christopher Roberts of the University of Delaware will give a talk titled “Opportunities for New Biophysical Characterization of Techniques for Therapeutic Proteins.” He will compared new and existing technologies to monitor protein aggregation and will discuss how those approaches can be used to leverage and provide new insights from a fundamental versus applied science perspective, as well as from the perspective of translating R&D methods to use in monitoring and controlling product quality during manufacturing.
The final presentation will be from Li Tao of Bristol-Myers Squibb, who will speak about the “Current Status of Analytical Development During Process Development for Biologics.” This presentation will cover analytical development centered around critical quality attributes strategy through the use of orthogonal technologies of liquid chromatography, electrophoresis, and mass spectrometry.
Fundamentals of Benchtop GC–MS Data Analysis and Terminology
April 5th 2025In this installment, we will review the fundamental terminology and data analysis principles in benchtop GC–MS. We will compare the three modes of analysis—full scan, extracted ion chromatograms, and selected ion monitoring—and see how each is used for quantitative and quantitative analysis.
Characterizing Plant Polysaccharides Using Size-Exclusion Chromatography
April 4th 2025With green chemistry becoming more standardized, Leena Pitkänen of Aalto University analyzed how useful size-exclusion chromatography (SEC) and asymmetric flow field-flow fractionation (AF4) could be in characterizing plant polysaccharides.
This information is supplementary to the article “Accelerating Monoclonal Antibody Quality Control: The Role of LC–MS in Upstream Bioprocessing”, which was published in the May 2025 issue of Current Trends in Mass Spectrometry.